Hyperfine (HYPR) said late Tuesday that it enrolled initial patients in a study that will assess the use of portable ultra-low-field magnetic resonance imaging, or MRI, in neurology offices.
The study will compare portable low-field MRI and conventional high-field MRI for pathology findings, clinical utility and patient experience, the company said.
Hyperfine said it plans to enroll 100 patients in the study and complete the trial by year-end.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。